When I analyze a company that has experienced a difficult period in the stock market, I always try to distinguish temporary challenges from structural problems. Novo Nordisk is currently one of the most interesting companies in the European pharmaceutical industry, as encouraging signs of improvement are beginning to emerge after a period of uncertainty.
The Danish pharmaceutical company is best known for Ozempic and Wegovy, two treatments that have transformed the diabetes and obesity markets.
However, Novo Nordisk has faced increasingly aggressive competition, particularly from Eli Lilly, along with pricing pressure and exceptionally high investor expectations.
What interests me today is whether the market has already priced too much negativity into Novo Nordisk's shares.The company's third-quarter 2026 results offer some encouraging indications.
Novo Nordisk reported revenue of DKK 79.2 billion, representing 4% growth at constant exchange rates, while adjusted operating profit increased 27% to DKK 31.7 billion.
I consider these figures important because they demonstrate improving commercial performance, although the increase in adjusted operating profit also benefited from a favorable comparison with the previous year.
Management also raised its full-year 2026 guidance, forecasting adjusted revenue growth between -2% and +2% at constant exchange rates.
This is certainly not explosive growth, but it could represent the beginning of a stabilization phase.
The development I find particularly promising is the oral version of Wegovy.
During the third quarter, the pill generated approximately DKK 5.4 billion in sales, demonstrating significant commercial interest.
I believe an oral obesity treatment could expand the addressable market by reaching patients who prefer tablets over injections.
Naturally, its long-term success will depend on pricing, insurance coverage, competition, and manufacturing capacity.
Another encouraging development concerns CagriSema, Novo Nordisk's next-generation obesity treatment.
In the REDEFINE 9 clinical trial, CagriSema demonstrated an average weight reduction of 21% after 68 weeks.
I consider this result promising, although regulatory approval and commercial success are not guaranteed.
Management is preparing for a potential US launch in 2027, subject to the necessary regulatory approvals.
From a financial perspective, I also find the company's valuation interesting.
A forward price-to-earnings ratio of approximately 10–11 times, as highlighted in the Seeking Alpha analysis, may appear relatively modest for a pharmaceutical company with established scientific expertise and globally recognized brands.
However, a low valuation multiple does not automatically mean a stock is undervalued.
The critical question is whether future earnings can remain sustainable, particularly given competition from Eli Lilly, pricing pressure, and the eventual expiration of certain patents.
I will closely monitor Wegovy's international expansion, operating margins, and management's outlook for 2027.
I am particularly interested in whether Novo Nordisk can strengthen its competitive position while protecting profitability.
My overall conclusion is cautiously optimistic.
Novo Nordisk possesses significant industrial capabilities, commercially established products, and a promising development pipeline that could support a renewed period of growth.
I do not consider a stock market recovery inevitable. Nevertheless, I believe that a return to sustainable earnings growth, combined with reasonable valuation multiples, could renew investor interest in the company.
For this reason, I will continue monitoring Novo Nordisk, looking for confirmation in its financial results rather than relying exclusively on market sentiment.
Because sometimes the most interesting investment opportunities emerge not when everything looks perfect, but when a fundamentally strong company begins demonstrating that it can overcome its challenges.

